Ro 90-7501, a Radiosensitizer, is an Aβ42 Fibril Assembly and PP5 Inhibitor

Cervical cancer is one of the most common cancers among women worldwide. Ro 90-7501 is an inhibitor of the amyloid β42 (Aβ42) fibril assembly. It is associated with Alzheimer’s disease. The usual method for Cervical cancer treatment is Radiotherapy, especially for locally advanced cancer. However, the treatment results are not satisfactory, the development of radiosensitizers is one of the strategies to improve the efficacy of radiotherapy. The present study aimed to elucidate the radiosensitizing effects of Ro 90-7501 and focused on ATM signaling after irradiation. In addition, Ro 90-7501 also inhibits protein phosphatase 5 (PP5) in a TPR-dependent manner.

Ro 90 7501 a Radiosensitizer is an Aβ42 Fibril Assembly and PP5 Inhibitor 2020 03 19 - Ro 90-7501, a Radiosensitizer, is an Aβ42 Fibril Assembly and PP5 Inhibitor

Ro 90-7501, an amyloid β42  fibril assembly inhibitor, has significant radiosensitizing effects on cervical cancer cells.

Ro 90-7501 is an amyloid β42 fibril assembly inhibitor that reduces Aβ42-induced cytotoxicity (EC50 of 2 μM). The combination of irradiation with Ro 90-7501 shows significant radiosensitizing effects in clonogenic survival and tumor growth delay assays. Ro 90-7501 significantly increases apoptosis and impairs cell cycle after irradiation. Western blotting shows that Ro 90-7501 suppresses the phosphorylation of ataxia telangiectasia mutated (ATM) and its downstream proteins, such as H2AX, Chk1, and Chk2, after irradiation. Ro 90-7501 inhibits DNA damage response by inhibiting ATM and has significant radiosensitizing effects on cervical cancer cells. In addition, TLRs and RLRs are two major types of PRRs. They recognize virus infection and induce an innate immune response. RO 90-7501 selectively enhances TLR3 and RLR ligand-induced IFN-β gene expression and antiviral response.

Ro 90-7501 significantly decreases tumor volume in the irradiation group. It has a radiosensitizing effect in vivo as well as in vitro.  Moreover, it induces cell-cycle arrest after irradiation, and it inhibits phosphorylation of ATM and its downstream proteins. In addition, RO 90–7501 is selectively enhancing TLR3 agonist-induced type I IFN production in both human kidney epithelial and macrophage cell lines. In summary, Ro 90-7501 has significant radiosensitizing effects on cervical cancer cells. It inhibits the phosphorylation of ATM and its downstream proteins, suppresses cell cycle progression, and increases apoptosis after irradiation.

Reference:

Tamari K, et al. Anticancer Res. 2019 Sep;39(9):4805-4810.;

Guo F, et al. PLoS One. 2012;7(10):e42583.